Genetic Cardiomyopathies Market Players:
- Becton Dickinson and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis International AG
- Merck & Co.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Mylan N.V.
- Boston Scientific Corporation
- Critical Care Diagnostics Inc.
- Bio-Rad Laboratories Inc.
- Sanofi S.A
- Roche Holding AG
- Astella Pharma
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of genetic cardiomyopathies is evaluated at USD 2.81 billion.
The global genetic cardiomyopathies market size was worth more than USD 2.51 billion in 2025 and is poised to witness a CAGR of over 13.2%, crossing USD 8.67 billion revenue by 2035.
North America genetic cardiomyopathies market is expected to capture a 38% share, underpinned by escalating investment in gene therapy research and development.
Key players in the market include Novartis International AG, Merck & Co., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Mylan N.V., Boston Scientific Corporation, Critical Care Diagnostics Inc., Bio-Rad Laboratories Inc., Roche Holding AG, AstraZeneca PLC, and Sanofi S.A.
